138 related articles for article (PubMed ID: 10550740)
1. Clinical and immunologic effects of a rush sublingual immunotherapy to Parietaria species: A double-blind, placebo-controlled trial.
Passalacqua G; Albano M; Riccio A; Fregonese L; Puccinelli P; Parmiani S; Canonica GW
J Allergy Clin Immunol; 1999 Nov; 104(5):964-8. PubMed ID: 10550740
[TBL] [Abstract][Full Text] [Related]
2. Rush sublingual immunotherapy in Parietaria allergic patients.
D'Ambrosio FP; Ricciardi L; Isola S; Savi E; Parmiani S; Puccinelli P; Musarra A
Allergol Immunopathol (Madr); 1996; 24(4):146-51. PubMed ID: 8939269
[TBL] [Abstract][Full Text] [Related]
3. Sublingual immunotherapy: a double-blind, placebo-controlled trial with Parietaria judaica extract standardized in mass units in patients with rhinoconjunctivitis, asthma, or both.
Purello-D'Ambrosio F; Gangemi S; Isola S; La Motta N; Puccinelli P; Parmiani S; Savi E; Ricciardi L
Allergy; 1999 Sep; 54(9):968-73. PubMed ID: 10505460
[TBL] [Abstract][Full Text] [Related]
4. Possible relationship between systemic side effects and sensitization to rPar j 2 in allergic patients submitted to an ultra-rush (20 min) sublingual immunotherapy and selected by component resolved diagnosis.
Rossi RE; Monasterolo G; Coco G; Operti D
Int Arch Allergy Immunol; 2005 Oct; 138(2):105-10. PubMed ID: 16174987
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of sublingual rush immunotherapy with grass allergen extracts. A double blind study.
Feliziani V; Lattuada G; Parmiani S; Dall'Aglio PP
Allergol Immunopathol (Madr); 1995; 23(5):224-30. PubMed ID: 8526180
[TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy and safety of preseasonal sublingual immunotherapy with grass pollen carbamylated allergoid in rhinitic patients. A double-blind, placebo-controlled study.
Palma-Carlos AG; Santos AS; Branco-Ferreira M; Pregal AL; Palma-Carlos ML; Bruno ME; Falagiani P; Riva G
Allergol Immunopathol (Madr); 2006; 34(5):194-8. PubMed ID: 17064648
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double-blind placebo-controlled study.
Bufe A; Ziegler-Kirbach E; Stoeckmann E; Heidemann P; Gehlhar K; Holland-Letz T; Braun W
Allergy; 2004 May; 59(5):498-504. PubMed ID: 15080830
[TBL] [Abstract][Full Text] [Related]
8. Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis.
Passalacqua G; Albano M; Fregonese L; Riccio A; Pronzato C; Mela GS; Canonica GW
Lancet; 1998 Feb; 351(9103):629-32. PubMed ID: 9500318
[TBL] [Abstract][Full Text] [Related]
9. Lack of effect of Timothy grass pollen sublingual immunotherapy tablet on birch pollen-induced allergic rhinoconjunctivitis in an environmental exposure unit.
Ellis AK; Tenn MW; Steacy LM; Adams DE; Day AG; Walker TJ; Nolte H
Ann Allergy Asthma Immunol; 2018 May; 120(5):495-503.e2. PubMed ID: 29432967
[TBL] [Abstract][Full Text] [Related]
10. Sublingual immunotherapy in patients with allergic rhinoconjunctivitis caused by ragweed pollen.
Skoner D; Gentile D; Bush R; Fasano MB; McLaughlin A; Esch RE
J Allergy Clin Immunol; 2010 Mar; 125(3):660-6, 666.e1-666.e4. PubMed ID: 20153030
[TBL] [Abstract][Full Text] [Related]
11. Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis.
La Rosa M; Ranno C; André C; Carat F; Tosca MA; Canonica GW
J Allergy Clin Immunol; 1999 Aug; 104(2 Pt 1):425-32. PubMed ID: 10452766
[TBL] [Abstract][Full Text] [Related]
12. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis.
Durham SR; Yang WH; Pedersen MR; Johansen N; Rak S
J Allergy Clin Immunol; 2006 Apr; 117(4):802-9. PubMed ID: 16630937
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of sublingual coseasonal immunotherapy with a monomeric allergoid in Cupressaceae pollen allergy--preliminary data.
Ariano R; Panzani RC; Mistrello G
Eur Ann Allergy Clin Immunol; 2005 Mar; 37(3):103-8. PubMed ID: 15918297
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of Juniperus ashei sublingual-swallow ultra-rush pollen immunotherapy in cypress rhinoconjunctivitis. A double-blind, placebo-controlled study.
Vervloet D; Birnbaum J; Laurent P; Hugues B; Fardeau MF; Massabie-Bouchat YP; Aferiat-Derome A; André C
Int Arch Allergy Immunol; 2007; 142(3):239-46. PubMed ID: 17114889
[TBL] [Abstract][Full Text] [Related]
15. Sublingual immunotherapy in pollen-induced seasonal rhinitis and conjunctivitis: a randomized controlled trial.
Mösges R; Brüning H; Hessler HJ; Götz G; Knaussmann HG
Acta Dermatovenerol Alp Pannonica Adriat; 2007 Dec; 16(4):143-8. PubMed ID: 18204744
[TBL] [Abstract][Full Text] [Related]
16. Randomized, double-blind, placebo-controlled trial of standardized ragweed sublingual-liquid immunotherapy for allergic rhinoconjunctivitis.
Creticos PS; Esch RE; Couroux P; Gentile D; D'Angelo P; Whitlow B; Alexander M; Coyne TC
J Allergy Clin Immunol; 2014 Mar; 133(3):751-8. PubMed ID: 24332263
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy with sublingual birch pollen extract. A short-term double-blind placebo study.
Horak F; Stübner P; Berger UE; Marks B; Toth J; Jäger S
J Investig Allergol Clin Immunol; 1998; 8(3):165-71. PubMed ID: 9684190
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of high dose sublingual immunotherapy in patients with rhinoconjunctivitis.
Worm M
Eur Ann Allergy Clin Immunol; 2006 Dec; 38(10):355-60. PubMed ID: 17274520
[TBL] [Abstract][Full Text] [Related]
19. Canadian trial of sublingual swallow immunotherapy for ragweed rhinoconjunctivitis.
Bowen T; Greenbaum J; Charbonneau Y; Hebert J; Filderman R; Sussman G; Del Carpio J; Gold M; Keith P; Moote W; Cecchetto S; Cecchetto O; Sharp D; Broutin O; André C
Ann Allergy Asthma Immunol; 2004 Nov; 93(5):425-30. PubMed ID: 15562880
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of 2 months of allergen-specific immunotherapy with Bet v 1-derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis: Results of a phase IIb study.
Spertini F; DellaCorte G; Kettner A; de Blay F; Jacobsen L; Jutel M; Worm M; Charlon V; Reymond C
J Allergy Clin Immunol; 2016 Jul; 138(1):162-8. PubMed ID: 27373329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
